Evommune, Inc.
Evommune is a clinical-stage biotechnology company developing innovative therapies targeting key drivers of chronic inflammatory diseases. The company's name does not appear with a ticker symbol on the cover page, though the filing indicates the company began trading on the New York Stock Exchange on November 6, 2025.… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Evommune, Inc. does
In the company’s own words
Evommune is a clinical-stage biotechnology company developing innovative therapies targeting key drivers of chronic inflammatory diseases. The company's name does not appear with a ticker symbol on the cover page, though the filing indicates the company began trading on the New York Stock Exchange on November 6, 2025. The company website is not disclosed in the provided excerpt.
Evommune's pipeline consists of two primary clinical-stage product candidates. EVO756 is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor found on mast cells and peripheral sensory neurons. The company is developing EVO756 for chronic spontaneous urticaria, atopic dermatitis, and additional indications including migraine, asthma, interstitial cystitis, and irritable bowel syndrome. EVO301 is a long-acting fusion protein consisting of an IL-18 binding protein and an anti-serum albumin Fab-associated domain, currently in Phase 2 development for moderate-to-severe atopic dermatitis and under evaluation for ulcerative colitis and other inflammatory conditions.
The company's approach focuses on identifying areas of highest unmet need in chronic inflammatory diseases and advancing molecules with high probability of improving patient outcomes. Evommune's management team has held leadership roles at over 25 companies and played key roles in discovering and developing nearly 30 approved small molecules and biologics, primarily in immunology and inflammation.
In May 2025, Evommune reported positive Phase 2 results for EVO756 in chronic inducible urticaria, demonstrating rapid clinical activity with 70 percent of observed patients showing improvement at four weeks. In February 2026, the company announced positive Phase 2a results for EVO301 in moderate-to-severe atopic dermatitis, meeting its primary efficacy endpoint at week 12 with highly statistically significant outcomes over placebo.
The company is advancing a portfolio of preclinical candidates for immunology and inflammation indications alongside its clinical programs. Evommune initiated a Phase 2b dose-ranging trial in chronic spontaneous urticaria in April 2025 and a Phase 2b dose-ranging trial in atopic dermatitis in August 2025, with initial results expected in 2026.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- PALO ALTO, CA
- Fiscal year end
- December
- CIK
- 2044725
- SIC
- 2834
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Evommune, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Evommune, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Evommune, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Evommune, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Evommune, Inc.'s last four quarterly filings that the numbers alone won't show?”